Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders

References

• Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797–803
   PubMed Web of Science ®Google Scholar
• Hogberg U. The World Health Report 2005: “make every mother and child count” – including Africans. Scand J Public Health 2005;33:409–11
   PubMed Web of Science ®Google Scholar
• Reinders LW, Mos CN, Thornton C, et al. Time poor: rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. Hypertens Pregnancy 2006;25:81–91
   PubMed Web of Science ®Google Scholar
• Oliveira SM, Arcuri EA, Santos JL. Cuff width influence on blood pressure measurement during the pregnant-puerperal cycle. J Adv Nurs 2002;38:180–9
   PubMed Web of Science ®Google Scholar
• Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia--eclampsia. Am J Obstet Gynecol 2009;200:481e1–7
   Google Scholar
• Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001;97:261–7
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895–903
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541–7; discussion 1547–50
   PubMed Web of Science ®Google Scholar
• Staff AC, Braekke K, Harsem NK, et al. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005;122:33–9
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Johnson DD, Chang EY, et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006;195:255–9
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818–24
   PubMed Web of Science ®Google Scholar
• Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010;43:768–70
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1–161.e11
   PubMed Web of Science ®Google Scholar
• Ohkuchi A, Hirashima C, Suzuki H, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt1 and PlGF levels in women with preeclampsia. Hypertens Res 2010;33:422–7
   PubMed Web of Science ®Google Scholar
• Stepan H, Schaarschmidt W, Jank A, et al. Use of angiogenic factors (sFlt1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience. Z Geburtshilfe Neonatol 2010;214:234–8
   PubMed Web of Science ®Google Scholar
• Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV
   PubMed Web of Science ®Google Scholar
• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67–75
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1–22
   PubMed Web of Science ®Google Scholar
• Acharya G, Wilsgaard T, Berntsen GK, et al. Reference ranges for serial measurements of blood velocity and pulsatility index at the intra-abdominal portion, and fetal and placental ends of the umbilical artery. Ultrasound Obstet Gynecol 2005;26:162–9
   PubMed Web of Science ®Google Scholar
• Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177–82
   PubMed Web of Science ®Google Scholar
• Woolcock J, Hennessy A, Xu B, et al. Soluble Flt-1 as a diagnostic marker of pre-eclampsia. Aust N Z J Obstet Gynaecol 2008;48:64–70
   Google Scholar
• Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010;202:40 e1–7
   Web of Science ®Google Scholar
• Salahuddin S, Lee Y, Vadnais M, et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:28 e1–6
   Web of Science ®Google Scholar
• Masuyama H, Suwaki N, Nakatsukasa H, et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006;194:551–6
   PubMed Web of Science ®Google Scholar
• Ohkuchi A, Hirashima C, Matsubara S, et al. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 2009;28:95–108
   PubMed Web of Science ®Google Scholar
• Young B, Levine RJ, Salahuddin S, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366–70
   PubMed Web of Science ®Google Scholar